Assignee profile:

Sanofi Pasteur

City:

Lyon

Country:

France

Published Applications:

28

Last publication date:

2026-05-21

Patent Grants:

19

Last grant date:

2026-03-10

Top Inventors for applications by Sanofi Pasteur

These are the the leading inventors for applications assigned to Sanofi Pasteur:

Recent patent applications by Sanofi Pasteur

Sanofi Pasteur based in Lyon, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-05-21
US20260137768A1
Human necessities

ZIKA VIRUS VACCINE

#2 | 2024-04-25 ✅ Patent 12,569,549 granted on 2026-03-10
US20240131142A1
Human necessities

FLAVIVIRUS VACCINE

#3 | 2024-01-25 ✅ Patent 12,496,335 granted on 2025-12-16
US20240024453A1
Human necessities

ZIKA VIRUS VACCINE

#4 | 2023-12-14
US20230398211A1
Human necessities

Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof

#5 | 2019-07-04
US20190201517A1
Human necessities

Vaccine Compositions

#6 | 2019-01-17 ✅ Patent 10,577,398 granted on 2020-03-03
US20190016760A1
Chemistry; metallurgy

Multimerization of recombinant protein by fusion to a sequence from lamprey

#7 | 2018-10-04 ✅ Patent 10,772,946 granted on 2020-09-15
US20180280491A1
Human necessities

Immunogenic compositions against

#8 | 2017-07-27 ✅ Patent 10,144,940 granted on 2018-12-04
US20170211111A1
Chemistry; metallurgy

Method for producing type B antigens

#9 | 2016-04-07 ✅ Patent 9,937,252 granted on 2018-04-10
US20160095916A1
Human necessities

Induction of cross-reactive cellular response against rhinovirus antigens

#10 | 2015-10-01
US20150273035A1
Human necessities

VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA

#11 | 2014-06-26
US20140178478A1
Human necessities

Immuno-Adjuvant Emulsion

#12 | 2014-02-06 ✅ Patent 9,028,839 granted on 2015-05-12
US20140037684A1
Human necessities

Stabilizing excipient for inactivated whole virus vaccine

#13 | 2013-01-31
US20130028934A1
Chemistry; metallurgy

Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses

#14 | 2012-02-23 ✅ Patent 9,019,496 granted on 2015-04-28
US20120044494A1
Physics

Method for estimating the amount of entities deposited on microparticles in suspension in a solution, associated device and use of said device

#15 | 2011-08-04 ✅ Patent 8,697,353 granted on 2014-04-15
US20110189226A1
Human necessities

Immunization compositions and methods

#16 | 2011-04-07 ✅ Patent 8,557,253 granted on 2013-10-15
US20110081380A1
Human necessities

Stabilizing excipient for inactivated whole virus vaccine

#17 | 2011-01-20 ✅ Patent 8,506,971 granted on 2013-08-13
US20110014272A1
Human necessities

Method for adjuvanting lipopolysaccharide (LPS) of gram-negative bacteria

#18 | 2010-12-30 ✅ Patent 9,132,181 granted on 2015-09-15
US20100330160A1
Human necessities

Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified strains of immunotype L6

#19 | 2010-11-18
US20100291192A1
Human necessities

Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria

#20 | 2010-10-14 ✅ Patent 8,961,997 granted on 2015-02-24
US20100260798A1
Human necessities

Method for purifying the rabies virus

#21 | 2010-05-06
US20100111990A1
Chemistry; metallurgy

Polypeptide Recognized by Anti HIV-1 GP41 Antibodies Isolated from Highly HIV-1 Exposed, Non Infected Women

#22 | 2010-01-21 ✅ Patent 8,142,795 granted on 2012-03-27
US20100015180A1
Chemistry; metallurgy

Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses

#23 | 2009-09-17 ✅ Patent 8,551,527 granted on 2013-10-08
US20090232894A1
Human necessities

Process for stabilizing an adjuvant containing vaccine composition

#24 | 2009-04-23
US20090104227A1
Human necessities

VACCINE COMPOSITION FOR THE PREVENTION OF CMV INFECTION

#25 | 2009-04-09 ✅ Patent 9,005,623 granted on 2015-04-14
US20090092620A1
Chemistry; metallurgy

Flu virus hemagglutinin specific monoclonal antibodies

#26 | 2009-03-26 ✅ Patent 7,871,807 granted on 2011-01-18
US20090081255A1
Human necessities

Method for producing the flu virus

#27 | 2008-01-17 ✅ Patent 7,718,357 granted on 2010-05-18
US20080014219A1
Human necessities

Method of immunization against the 4 dengue serotypes

#28 | 2007-01-18 ✅ Patent 8,703,095 granted on 2014-04-22
US20070014805A1
Human necessities

Immuno-adjuvant emulsion

Also check out Sanofi Pasteur's (Lyon, France) applicant profile with 4 patent applications submitted.

AssigneeID:

7109 ⎘